Dysregulation of renal transient receptor potential melastatin 6/7 but not paracellin-1 in aldosterone-induced hypertension and kidney damage in a model of hereditary hypomagnesemia

Rationale Hyperaldosteronism, important in hypertension, is associated with electrolyte alterations, including hypomagnesemia, through unknown mechanisms. Objective To test whether aldosterone influences renal Mg2+ transporters, (transient receptor potential melastatin (TRPM) 6, TRPM7, paracellin-1) leading to hypomagnesemia, hypertension and target organ damage and whether in a background of magnesium deficiency, this is exaggerated. Methods and results Aldosterone effects in mice selectively bred for high-normal (MgH) or low (MgL) intracellular Mg2+ were studied. Male MgH and MgL mice received aldosterone (350 μg/kg per day, 3 weeks). SBP was elevated in MgL. Aldosterone increased blood pressure and albuminuria and increased urinary Mg2+ concentration in MgH and MgL, with greater effects in MgL. Activity of renal TRPM6 and TRPM7 was lower in vehicle-treated MgL than MgH. Aldosterone increased activity of TRPM6 in MgH and inhibited activity in MgL. TRPM7 and paracellin-1 were unaffected by aldosterone. Aldosterone-induced albuminuria in MgL was associated with increased renal fibrosis, increased oxidative stress, activation of mitogen-activated protein kinases and nuclear factor-NF-κB and podocyte injury. Mg2+ supplementation (0.75% Mg2+) in aldosterone-treated MgL normalized plasma Mg2+, increased TRPM6 activity and ameliorated hypertension and renal injury. Hence, in a model of inherited hypomagnesemia, TRPM6 and TRPM7, but not paracellin-1, are downregulated. Aldosterone further decreased TRPM6 activity in hypomagnesemic mice, a phenomenon associated with hypertension and kidney damage. Such effects were prevented by Mg2+ supplementation. Conclusion Amplified target organ damage in aldosterone-induced hypertension in hypomagnesemic conditions is associated with dysfunctional Mg2+-sensitive renal TRPM6 channels. Novel mechanisms for renal effects of aldosterone and insights into putative beneficial actions of Mg2+, particularly in hyperaldosteronism, are identified.

[1]  P. Sarafidis,et al.  Oral magnesium supplementation reduces ambulatory blood pressure in patients with mild hypertension. , 2009, American journal of hypertension.

[2]  H. van Goor,et al.  Aldosterone Induces Apoptosis in Rat Podocytes: Role of PI3-K/Akt and p38MAPK Signaling Pathways , 2009, Nephron Experimental Nephrology.

[3]  J. Hou,et al.  Insights into Driving Forces and Paracellular Permeability from Claudin‐16 Knockdown Mouse , 2009, Annals of the New York Academy of Sciences.

[4]  E. Frohlich Current challenges and unresolved problems in hypertensive disease. , 2009, The Medical clinics of North America.

[5]  A. Mihailidou,et al.  Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology , 2009, Molecular and Cellular Endocrinology.

[6]  R. Touyz,et al.  Dysregulation of Vascular TRPM7 and Annexin-1 Is Associated With Endothelial Dysfunction in Inherited Hypomagnesemia , 2009, Hypertension.

[7]  A. Mazur,et al.  Vascular function of MGH and MGL mice, two strains which differ by a genetic variation of magnesium metabolism. , 2008, Magnesium research.

[8]  J. Hoenderop,et al.  Molecular determinants of magnesium homeostasis: insights from human disease. , 2008, Journal of the American Society of Nephrology : JASN.

[9]  W. T. Groenestege,et al.  Relationship between low magnesium status and TRPM6 expression in the kidney and large intestine. , 2008, American journal of physiology. Regulatory, integrative and comparative physiology.

[10]  Afzal Shah,et al.  Potassium, Calcium, Magnesium, and Sodium Levels in Biological Samples of Hypertensive and Nonhypertensive Diabetes Mellitus Patients , 2008, Biological Trace Element Research.

[11]  R. Touyz,et al.  Downregulation of Renal TRPM7 and Increased Inflammation and Fibrosis in Aldosterone-Infused Mice: Effects of Magnesium , 2008, Hypertension.

[12]  R. Touyz Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular biology: implications in hypertension. , 2008, American journal of physiology. Heart and circulatory physiology.

[13]  J. Hoenderop,et al.  Calciotropic and magnesiotropic TRP channels. , 2008, Physiology.

[14]  A. Berthelot,et al.  A long-term moderate magnesium-deficient diet aggravates cardiovascular risks associated with aging and increases mortality in rats , 2008, Journal of hypertension.

[15]  M. Barbagallo,et al.  Magnesium metabolism in hypertension and type 2 diabetes mellitus. , 2007, American journal of therapeutics.

[16]  G. Adler,et al.  Aldosterone: villain or protector? , 2007, Hypertension.

[17]  E. Schiffrin,et al.  Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. , 2007, Clinical science.

[18]  Z. Zuo,et al.  Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. , 2007, Journal of cardiac failure.

[19]  F. Luft,et al.  Aldosterone, mineralocorticoid receptors, and vascular inflammation , 2007, Current opinion in nephrology and hypertension.

[20]  R. Touyz,et al.  Role of magnesium in hypertension. , 2007, Archives of biochemistry and biophysics.

[21]  R. Penner,et al.  TRPM7 Channel Is Regulated by Magnesium Nucleotides via its Kinase Domain , 2006, The Journal of general physiology.

[22]  D. Clapham,et al.  Functional TRPM7 Channels Accumulate at the Plasma Membrane in Response to Fluid Flow , 2006, Circulation research.

[23]  C. Figdor,et al.  TRPM7, a novel regulator of actomyosin contractility and cell adhesion , 2006, The EMBO journal.

[24]  A. Perraud,et al.  The Channel Kinases TRPM6 and TRPM7 Are Functionally Nonredundant* , 2005, Journal of Biological Chemistry.

[25]  E. Schiffrin,et al.  Calcium, magnesium, and oxidative stress in hyperaldosteronism. , 2005, Circulation.

[26]  R. Touyz,et al.  Transient Receptor Potential Melastatin 7 Ion Channels Regulate Magnesium Homeostasis in Vascular Smooth Muscle Cells: Role of Angiotensin II , 2005, Circulation research.

[27]  K. Weber,et al.  70 HYPERPARATHYROIDISM AND THE CALCIUM PARADOX OF ALDOSTERONISM , 2005, Journal of Investigative Medicine.

[28]  F. Wolf,et al.  Magnesium metabolism in mice selected for high and low erythrocyte magnesium levels. , 2004, Metabolism: clinical and experimental.

[29]  Lillia V. Ryazanova,et al.  Characterization of the Protein Kinase Activity of TRPM7/ChaK1, a Protein Kinase Fused to the Transient Receptor Potential Ion Channel* , 2004, Journal of Biological Chemistry.

[30]  F. Luft Mendelian forms of human hypertension and mechanisms of disease. , 2003, Clinical medicine & research.

[31]  A. Mokdad,et al.  Dietary magnesium intake in a national sample of US adults. , 2003, The Journal of nutrition.

[32]  R. Touyz,et al.  Effects of low dietary magnesium intake on development of hypertension in stroke-prone spontaneously hypertensive rats: role of reactive oxygen species , 2002, Journal of hypertension.

[33]  E. Haddad,et al.  Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family , 2002, Nature Genetics.

[34]  P. Houillier,et al.  Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. , 2001, Kidney international.

[35]  M. Nadler,et al.  LTRPC7 is a Mg·ATP-regulated divalent cation channel required for cell viability , 2001, Nature.

[36]  T. Hostetter,et al.  Aldosterone in renal disease. , 2001, Current opinion in nephrology and hypertension.

[37]  R. Touyz,et al.  Physiological and pathophysiological role of magnesium in the cardiovascular system: implications in hypertension , 2000, Journal of hypertension.

[38]  R. Touyz,et al.  Magnesium supplementation attenuates, but does not prevent, development of hypertension in spontaneously hypertensive rats. , 1999, American journal of hypertension.

[39]  B. Altura,et al.  Mg2+ modulates membrane sphingolipid and lipid second messenger levels in vascular smooth muscle cells , 1998, FEBS letters.

[40]  H. Francès,et al.  Mice Selected for Low and High Blood Magnesium Levels: A New Model for Stress Studies , 1997, Physiology & Behavior.

[41]  A. Hofman,et al.  Dietary electrolyte intake and blood pressure in older subjects: the Rotterdam Study , 1996, Journal of hypertension.

[42]  C. Dotti,et al.  Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. , 1995, American journal of hypertension.

[43]  J. Kantelip,et al.  Dietary magnesium supplementation modifies blood pressure and cardiovascular function in mineralocorticoid-salt hypertensive rats but not in normotensive rats. , 1995, The Journal of nutrition.

[44]  M. Bara,et al.  Magnesium and blood pressure. II. Clinical studies. , 1992, Magnesium research.

[45]  D. Reed,et al.  Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. , 1987, The American journal of clinical nutrition.

[46]  V. Faber,et al.  THE TOXICITY OF CADMIUM , 1964, Lancet.

[47]  R. Horton,et al.  Effect of aldosterone on the metabolism of magnesium. , 1962, The Journal of clinical endocrinology and metabolism.

[48]  I. Macintyre,et al.  The influence of aldosterone on magnesium metabolism. , 1960, Lancet.

[49]  N. Knoers,et al.  New molecular players facilitating Mg(2+) reabsorption in the distal convoluted tubule. , 2010, Kidney international.

[50]  A. Romani Magnesium homeostasis in mammalian cells. , 2007, Frontiers in bioscience : a journal and virtual library.

[51]  K. Weber,et al.  Calcium paradox of aldosteronism and the role of the parathyroid glands. , 2006, American journal of physiology. Heart and circulatory physiology.

[52]  P. Brazzarola,et al.  Intralymphocyte free magnesium in patients with primary aldosteronism: aldosterone and lymphocyte magnesium homeostasis. , 2000, Hypertension.

[53]  F. Cappuccio,et al.  Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. , 1988, Nephron.